Antiangiogenic approaches to age-related macular degeneration in the future.
Neovascular age-related macular degeneration (AMD) is a complex disease that likely involves multiple angiogenic agents that contribute to the development of choroidal neovascularization (CNV). Although inhibition of vascular endothelial growth factor with ranibizumab has demonstrated efficacy and safety in the treatment of neovascular AMD, novel treatments targeting different mechanisms that play a role in CNV development currently are being investigated. Data from these clinical trials will increase our knowledge of the pathogenesis of AMD and likely provide additions to the treatment armamentarium for improving vision and quality of life in patients with AMD.
The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA. ddo@jhmi.edu
Diana V
DV
Do
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D020256:Choroidal Neovascularization / Q000628:therapy*; D003131:Combined Modality Therapy; D017242:Complement Factor H / Q000235:genetics; D005544:Forecasting; D006801:Humans; D008268:Macular Degeneration / Q000628:therapy*; D010982:Platelet-Derived Growth Factor / Q000037:antagonists & inhibitors; D011878:Radiotherapy
D020533:Angiogenesis Inhibitors; C493495:CFH protein, human; D010982:Platelet-Derived Growth Factor; D017242:Complement Factor H